Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?Investors Business Daily • 12/16/24
Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland ChinaPRNewsWire • 12/15/24
2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be CautiousThe Motley Fool • 12/15/24
Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's diseasePRNewsWire • 12/13/24
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer StudyZacks Investment Research • 12/12/24
Telehealth firm Ro to provide single-dose vials of Lilly's Zepbound to obesity patientsReuters • 12/11/24
Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast CancerPRNewsWire • 12/11/24
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli LillyCNBC • 12/11/24
Lilly CEO says tax and regulation reform, drug affordability are focuses under TrumpReuters • 12/10/24
Eli Lilly, maker of King Kong of weight loss jabs, weighs in with monster $15bn buybackProactive Investors • 12/10/24
Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual MeetingPRNewsWire • 12/09/24
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increasePRNewsWire • 12/09/24
CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® ParadePRNewsWire • 12/09/24
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety ConcernsBenzinga • 12/09/24
The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking TherapeuticsZacks Investment Research • 12/09/24